Novo Nordisk announced on March 10, 2025, that its CagriSema trial showed significant weight loss results in adults with obesity or type 2 diabetes, achieving 15.7% weight loss versus 3.1% with placebo. The trial, involving 1,206 participants, also reported that 89.7% of patients on CagriSema lost at least 5% of their body weight, indicating strong efficacy and good safety profile.